XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (3884)	9/24/1997 3:39:00 AM
From: Webhead	of 17367

Actually, I think that this is a phase I study (though i'm sure that they'll build a little efficacy testing into it so it may be more a phase I/II). It's unlikely that there will be much of a safety problem given the large number of people who have recieved BPI. However, because some CF patients have antibodies directed against BPI it will be important to determine the pharmokinetics in patients +/- BPI antibodiess to nail down the actual indication. It's also possible that patients with BPI antibodies might react to BPI injections unfavorably so safety might be a non-trivial concern. just my 0.02 Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next